# Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

> **NCT02855268** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 43 (actual)

## Conditions studied

- Alport Syndrome

## Interventions

- **DRUG:** lademirsen (SAR339375)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02855268
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-02
- **Primary completion:** 2022-09-22
- **Final completion:** 2022-09-22
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** The results of the futility analysis led to the study termination. No unexpected safety findings were identified.
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855268, "Study of Lademirsen (SAR339375) in Patients With Alport Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02855268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*